Bharat Parenterals share price
NSE: BPLPHARMABSE: 541096Pharmaceuticals & BiotechnologySmall Cap
Bharat Parenterals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2018
Last close ₹1,912.90up ₹26.10 (1.38%)BSE ₹1,918.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,886.80.
28 Oct: open ₹1,882.00, high ₹1,930.00, low ₹1,869.80
52-week range of BSE trades to 28 Oct 2026
₹880.25Low, 30 Mar 2026₹2,274.10High, 28 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,318 Cr1,597th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Owners' profit not stated
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.05%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −5.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,76945.5% delivered
Results
Consolidated; ₹ crore.Bharat Parenterals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −11.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹94 Crdown 5.91%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹3.56 CrQuarter to Mar 2026: −₹8.16 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- −3.8%
Revenue by quarter
Peak revenue ₹116 Cr, quarter to Jun 2025; lowest ₹65 Cr, quarter to Sep 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 8 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 72 | 72 | 104 | 116 | 65 | 65 | 100 | 94 |
| Net profit | −18 | −8 | −9 | −1 | −9 | −10 | −8 | −4 |
| Net margin | −24.5% | −10.9% | −9.1% | −0.8% | −13.3% | −14.8% | −8.2% | −3.8% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹345 Crup 1.48%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹27 CrYear to Mar 2025: −₹44 Cr
- Net margin
- −7.9%
Revenue by year
Peak revenue ₹345 Cr, year to Mar 2026; lowest ₹139 Cr, year to Mar 2018
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 2 of the 9 years shown
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139 | 220 | 228 | 205 | 212 | 218 | 257 | 340 | 345 |
| Net profit | 9 | 21 | 24 | 20 | 21 | 16 | 11 | −44 | −27 |
| Net margin | 6.6% | 9.7% | 10.6% | 9.9% | 9.8% | 7.2% | 4.1% | −12.8% | −7.9% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a quarter's profit for shareholders does not agree with its own earnings per share.Bharat Parenterals PE ratio and valuation
Price to book
At or below today's level on 89% of 1,072 trading days over the last 5 years.
LowestHighest
Its median2.10Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 67% of 2,032 trading days since Apr 2018.
LowestHighest
Its median0.00%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −8.7% | – | – | 0.1% |
| 3 years | +39.0% | – | – | 0.1% |
| 5 years | +22.0% | – | – | 0.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
1 fund disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 WhiteOak Capital Pharma and Healthcare FundWhiteOak Capital Mutual Fund | 5,045 | 0.10% | ₹0.90 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Bharat Parenterals insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group2 purchases, 0 sales₹0.31 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.31 Cr
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Bharat Parenterals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Bharat Parenterals in market cap.Healthcare companies
Bharat Parenterals is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Venus RemediesVENUSREM | 1,778 | 14.61 | 2.52 | +19.3% | +73.0% | 18.7% | 21.0% | 0.75% |
 NGL Fine-ChemNGLFINE | 1,613 | 28.20 | 4.90 | +40.5% | – | 18.7% | 14.5% | 0.07% |
 Jagsonpal PharmaceuticalsJAGSNPHARM | 1,526 | 33.54 | 6.34 | +6.4% | −26.6% | 18.3% | 21.7% | 1.73% |
 Amrutanjan Health CareAMRUTANJAN | 1,425 | 26.41 | 3.85 | +10.7% | −1.0% | 15.5% | 18.0% | 0.99% |
 Fermenta BiotechFERMENTA | 1,303 | – | 3.21 | −3.2% | – | – | 13.5% | 0.85% |
 Anlon HealthcareAHCL | 1,301 | 44.76 | 5.65 | – | – | 13.9% | 18.0% | 0.00% |
 KopranKOPRAN | 1,220 | 48.83 | 2.30 | +12.0% | −28.4% | 4.8% | 6.2% | 1.19% |
 Lincoln PharmaceuticalsLINCOLN | 1,118 | 11.59 | 1.48 | +10.2% | +11.7% | 13.5% | 11.3% | 0.32% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Bharat Parenterals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.00 a share, years to Mar 2024, Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 11 Sep 2026 | Final | ₹1.00 |
| 19 Sep 2025 | Final | ₹1.00 |
| 25 Jun 2024 | Final | ₹1.00 |
| 25 Sep 2023 | Final | ₹0.75 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Bharat Parenterals announcements
Oct 2026
26 Oct · Board meeting
Meeting on 29 Oct 2026: quarterly results25 Oct · Meeting
24 Oct · Analysts
Bharat Parenterals share price by year
Each calendar year to 2025.Bharat Parenterals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 1,209.45 | −17.6% | 1,640.90 | 837.65 |
| 2024BSE close | 1,467.75 | +81.2% | 1,830.85 | 758.50 |
| 2023BSE close | 810.10 | +147.0% | 840.95 | 318.35 |
| 2022BSE close | 328.00 | −14.4% | 506.85 | 311.70 |
| 2021BSE close | 383.30 | +8.8% | 478.25 | 335.10 |
| 2020BSE close | 352.25 | +119.8% | 503.30 | 133.00 |
| 2019BSE close | 160.25 | −16.7% | 251.90 | 152.25 |
| 2018BSE close | 192.30 | – | 324.80 | 121.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2018 is from its first session, 21 Mar 2018.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,796.70 | 1,920.00 | 1,788.40 | 1,886.80 | 1,863.57 | 11,972 | 66.6% |
| 26 Oct 2026 | 1,719.00 | 1,896.10 | 1,680.00 | 1,802.20 | 1,796.28 | 12,181 | 31.4% |
| 23 Oct 2026 | 1,794.00 | 1,794.00 | 1,650.00 | 1,690.00 | 1,697.70 | 3,089 | 40.3% |
| 22 Oct 2026 | 1,745.10 | 1,800.00 | 1,745.00 | 1,776.00 | 1,772.35 | 1,741 | 51.4% |
| 21 Oct 2026 | 1,787.90 | 1,914.20 | 1,732.10 | 1,758.80 | 1,823.43 | 22,496 | 15.6% |
| 19 Oct 2026 | 1,800.00 | 1,803.80 | 1,704.00 | 1,729.50 | 1,741.93 | 4,366 | 36.1% |
| 16 Oct 2026 | 1,878.00 | 1,881.20 | 1,788.10 | 1,804.00 | 1,815.44 | 2,115 | 49.7% |
| 15 Oct 2026 | 1,914.00 | 1,925.00 | 1,861.00 | 1,865.70 | 1,883.80 | 1,845 | 62.2% |
| 14 Oct 2026 | 1,878.40 | 1,923.70 | 1,844.10 | 1,899.80 | 1,895.52 | 3,946 | 58.3% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Chairperson and managing director
- BHARATKUMAR RAMESHCHANDRA DESAI
- At the end of the quarter to Sep 2026
- NSE symbol
- BPLPHARMA
- BSE code
- 541096
- ISIN
- INE365Y01019
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.bplindia.in
- CIN
- L24231GJ1992PLC018237
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1992
- Registered office
- Survey No.144A, Jarod Samlaya Road, Haripura, Savli, Vadodara 391520, Gujarat
- Share registrar
- Adroit Corporate Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments